JERUSALEM, September 20, 2022 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. BVXV, which focuses on the development, manufacturing and marketing of innovative products for the prevention and treatment of infectious diseases and other diseases, today gave encouraging news related to the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences (MPG) and Universitätsmedizin known Zentrum Göttingen (UMG) for the development of a pipeline of innovative, alpaca-derived nano-antibody (NanoAb) therapies.

As reported in March 2022In addition to an exclusive license for ongoing development and commercialization of an inhaled COVID-19 NanoAb therapy, the parties have a five-year Research Collaboration Agreement (RCA) for additional NanoAbs to treat diseases such as psoriasis, psoriatic arthritis, asthma and wet macular degeneration. Today BiondVax reported about it professor Dirk Gorlich von MPG and his team have successfully generated, identified and isolated NanoAbs that address a number of additional biological targets as specified in the corresponding RCA. Professor Görlich and his colleague professor Mathias Dobbelstein from UMG confirmed a strong affinity of the new NanoAbs to their biological target molecules and a high thermostability. The academic research teams have also demonstrated strong neutralization of their respective target molecules by several NanoAb candidates. Studies to neutralize the other NanoAbs are scheduled to begin later this year.

Based on these promising results, the BiondVax-MPG-UMG Joint Steering Committee set up to guide the NanoAb collaboration decided earlier this month to focus on further development, starting with the following NanoAbs targeting immune system cytokines aim:

1. NanoAbs targeting IL-17A, IL-17F and the IL-17A/F complex as drug candidates for the potential treatment of psoriasis and psoriatic arthritis.
2. NanoAbs against IL-13 and NanoAbs against TSLP as…